Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Idexx Laboratories, Inc. Revenue & Financial Statements
Idexx Laboratories, Inc. reported revenue of $4.3B for the fiscal year ended December 31, 2025, up 10.4% year over year, with net income of $1.1B and diluted EPS of $13.08.
- Company
- Idexx Laboratories, Inc. IDXX · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 3.4B | 3.7B | 3.9B | 4.3B |
| Cost of revenue | 1.3B | 1.4B | 1.5B | 1.5B | 1.6B |
| Gross profit | 1.9B | 2.0B | 2.2B | 2.4B | 2.7B |
| Operating income | 932.0M | 898.8M | 1.1B | 1.1B | 1.4B |
| Pretax income | 690.0M | 684.7M | 889.1M | 897.3M | 266.6M |
| Net income | 744.8M | 679.1M | 845.0M | 887.9M | 1.1B |
| Diluted EPS | 8.60 | 8.03 | 10.06 | 10.67 | 13.08 |
| EBITDA | 1.0B | 1.0B | 1.2B | 1.3B | 1.5B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 964.1M | 1.0B | 975.5M | 954.3M | 998.4M | 1.1B | 1.1B | 1.1B |
| Cost of revenue | 371.0M | 384.4M | 379.5M | — | 375.0M | 414.7M | 421.9M | 432.5M |
| Gross profit | 593.1M | 619.2M | 596.0M | 570.7M | 623.4M | 694.7M | 683.4M | 658.1M |
| Operating income | 299.0M | 263.8M | 303.9M | 261.7M | 316.5M | 373.0M | 354.8M | 315.6M |
| Pretax income | 295.5M | 259.1M | 298.9M | 256.4M | 310.1M | 362.4M | 344.8M | 307.0M |
| Net income | 235.6M | 203.3M | 232.8M | 216.1M | 242.7M | 294.0M | 274.6M | 248.2M |
| Diluted EPS | 2.81 | 2.44 | 2.80 | 2.62 | 2.96 | 3.63 | 3.40 | 3.09 |
| EBITDA | 328.9M | — | 338.0M | 295.4M | 350.6M | — | 391.5M | 354.3M |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 2.4B | 2.7B | 3.3B | 3.3B | 3.4B |
| Current assets | 955.7M | 1.1B | 1.5B | 1.4B | 1.4B |
| Cash & equivalents | 144.5M | 112.5M | 453.9M | 288.3M | 180.1M |
| Total liabilities | 1.7B | 2.1B | 1.8B | 1.7B | 1.7B |
| Current liabilities | 763.6M | 1.2B | 951.5M | 1.1B | 1.1B |
| Long-term debt | 775.2M | 694.4M | 622.9M | 449.8M | 374.8M |
| Total debt | 850.2M | 769.4M | 697.9M | 617.6M | 449.8M |
| Stockholders’ equity | 690.0M | 608.7M | 1.5B | 1.6B | 1.6B |
| Net debt | 705.7M | 656.8M | 243.9M | 329.3M | 269.8M |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 755.5M | 543.0M | 906.5M | 929.0M | 1.2B |
| Investing cash flow | (293.0M) | (195.3M) | (125.3M) | (207.1M) | (136.2M) |
| Financing cash flow | (697.4M) | (370.9M) | (442.0M) | (878.1M) | (1.2B) |
| Capital expenditure | 119.5M | 148.8M | 133.6M | 120.9M | 124.7M |
| Free cash flow | 636.0M | 394.1M | 772.9M | 808.1M | 1.1B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 37.8M | 49.8M | 59.7M | 60.3M | 60.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every IDXX filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.